5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients

Pharmacological Reports

Volumn 60, Issue 2, 2008, Pages 238-242

  Sulzyc Bielicka, Violetta ^a   Bińczak Kuleta, Agnieszka ^a   Pioch, Wiesława ^a   Kładny, Józef ^a   Gziut, Katarzyna ^a   Bielicki, Dariusz ^a   Ciechanowicz, Andrzej ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

5 fluorouracil toxicity; Dihydropyrimidine dehydrogenase; Gene mutation

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; ALLELE; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; COLORECTAL CANCER; COLORECTAL SURGERY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHARMACOGENETICS; POLAND; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 49749106675     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ahluwalia R, Freimuth R, McLeod HL, Marsh S: Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem, 2003, 49, 1661-1664.
2. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S: Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest, 2002, 20, 333-339.
3. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics, 2000, 10, 217-223.
4. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest, 1988, 81, 47-51.
5. Fischer J, Schwab M, Eichelbaum M, Zanger UM: Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test, 2003, 7, 97-105.
6. Gross E, Seck K, Neubauer S, Mayr J, Hellebrand H, Ratanaphan A, Lutz V et al.: High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol, 2003, 22, 325-332.
7. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase ( DPYD) in the Egyptian population. Br J Clin Pharmacol, 2002, 53, 596-603.
8. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF: Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol, 2004, 53, 445-451.
9. Johnson MR, HageboutrosA, Wang K, High L, Smith JB, Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res, 1999, 5, 2006-2011.
10. Kouwaki M, Hamajima. N, Sumi S, Nonaka M, Sasaki M, Dobashi K, Kidouchi K et al.: Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res, 1998, 4, 2999-3004.
11. Maitland ML, Vasisht K, Ratain MJ: TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?, Trends Pharmacol Sci, 2006, 27, 432-437.
12. National Cancer Institute 1999 Common toxicity criteria, version 2.0. http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf.
13. Raida M, Schwabe W, Hausler P, Van Kuilenburg ABP, Van Gennip AH, Behnke D, Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res, 2001, 7, 2832-2839.
14. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol, 1998, 46, 151-156.
15. Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer, 1998, 77, 497-500.
16. Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML, Sanches E et al.: Mutation in exon 14 dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med, 2004, 6, 102-107.
17. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M et al.: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res, 2005, 11, 5886-5892.
18. Suzen HS, Yuce N, Guvenc G, Duydu Y, Erke T: TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol, 2005, 61, 881-885.
19. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med, 1985, 313, 245-249.
20. Van Kuilenburg ABP, De Abreu RA, Van Gennip AH: Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem, 2003, 40, 41-45.
21. Van Kuilenburg ABP, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, Maropoulos GD et al.: Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J, 2002, 364, 157-163.
22. Van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG et al.: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res, 2000, 6, 4705-4712.
23. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer, 2002, 101, 253-258.
24. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + IG > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics, 2002, 12, 555-558.
25. Van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HP, Bass F et al.: Lethal outcome of patient with complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res, 2001, 7, 1149-1153.
26. Van Kuilenburg ABP, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, van Gennip AH: Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer, 1997, 33, 2258-2264.
27. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics, 1998, 51, 391-400.
28. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernadez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest, 1996, 98, 610-615.
29. Yamaguchi K, Arai Y, Kanda Y, Akagi K: Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res, 2001, 92, 337-342.